New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
(WorldNews Health)

http://www.businesswire.com/news/home/20171211005225/en/ ALPROLIX is a recombinant clotting factor IX therapy developed using Fc fusion technology to prolong circulation in the body. ALPROLIX has the longest real-world experience of any hemophilia B extended half-life therapy and has been studied in more than 150 adult, adolescent, and pediatric patients over three years as part of a robust clinical development program and an extension study. Using data from the pivotal Phase 3 B-LONG study of 123 patients with severe hemophilia B, and B-YOND, the long-term extension study of ALPROLIX that included 93 patients from B-LONG, researchers evaluated long-term outcomes of 22 study participants...